| HOME >> BIOLOGY >> TECHNOLOGY |
outstanding; respectively, at
March 31, 2008 and December 31, 2007 2,209 2,209
Additional paid-in capital 127,278,108 126,490,647
Accumulated other comprehensive income 1,260,704 1,481,779
Accumulated deficit (92,420,179) (87,402,551)
Total stockholders' equity 36,120,842 40,572,084
Total liabilities and stockholders'
equity $62,223,155 $66,611,132
PharmAthene, Inc.
Consolidated Statements of Operations
(Unaudited)
Three months ended March 31,
2008 2007
(unaudited)
Contract and grant revenue $5,819,054 $2,961,759
Other revenue 21,151 7,000
5,840,205 2,968,759
Operating expenses:
Research and development 5,877,055 3,091,604
General and administrative 4,678,723 2,479,825
Depreciation and amortization 196,103 147,133
Total operating expenses 10,751,881 5,718,562
Loss from operations (4,911,676) (2,749,803)
Other income (expense):
Interest income 471,765 55,616
Interest expense (666,997) (241,781)
Change in market value of derivative
instruments 89,280 7,626
Total other expense (105,952)
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved |